Compugen: A Stock To Keep

Compugen (CGEN) cancer immunotherapy’s predictive target computational discovery platforms enabled it to identify two checkpoint proteins, PVRIG and TIGIT, when nobody else could. Compugen’s technological capability has also enabled it to create therapeutic inhibitors of its two discovered targets.

The discoveries happened to be important in improving cancer immunotherapy. The lead therapeutic candidate, COM701 . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.